Literature DB >> 25697362

NADPH oxidase-generated hydrogen peroxide induces DNA damage in mutant FLT3-expressing leukemia cells.

Joanna Stanicka1, Eileen G Russell1, John F Woolley1, Thomas G Cotter2.   

Abstract

Internal tandem duplication of the FMS-like tyrosine kinase (FLT3-ITD) receptor is present in 20% of acute myeloid leukemia (AML) patients and it has been associated with an aggressive AML phenotype. FLT3-ITD expressing cell lines have been shown to generate increased levels of reactive oxygen species (ROS) and DNA double strand breaks (DSBs). However, the molecular basis of how FLT3-ITD-driven ROS leads to the aggressive form of AML is not clearly understood. Our group has previously reported that inhibition of FLT3-ITD signaling results in post-translational down-regulation of p22(phox), a small membrane-bound subunit of the NADPH oxidase (NOX) complex. Here we demonstrated that 32D cells, a myeloblast-like cell line transfected with FLT3-ITD, have a higher protein level of p22(phox) and p22(phox)-interacting NOX isoforms than 32D cells transfected with the wild type FLT3 receptor (FLT3-WT). The inhibition of NOX proteins, p22(phox), and NOX protein knockdowns caused a reduction in ROS, as measured with a hydrogen peroxide (H2O2)-specific dye, peroxy orange 1 (PO1), and nuclear H2O2, as measured with nuclear peroxy emerald 1 (NucPE1). These reductions in the level of H2O2 following the NOX knockdowns were accompanied by a decrease in the number of DNA DSBs. We showed that 32D cells that express FLT3-ITD have a higher level of both oxidized DNA and DNA DSBs than their wild type counterparts. We also observed that NOX4 and p22(phox) localize to the nuclear membrane in MV4-11 cells expressing FLT3-ITD. Taken together these data indicate that NOX and p22(phox) mediate the ROS production from FLT3-ITD that signal to the nucleus causing genomic instability.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  DNA Damage; Genomic Instability; Leukemia; NADPH Oxidase; Oncogene; Reactive Oxygen Species (ROS); Redox

Mesh:

Substances:

Year:  2015        PMID: 25697362      PMCID: PMC4392242          DOI: 10.1074/jbc.M113.510495

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Single-strand interruptions in replicating chromosomes cause double-strand breaks.

Authors:  A Kuzminov
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

2.  New insight into the Nox4 subcellular localization in HEK293 cells: first monoclonal antibodies against Nox4.

Authors:  Leilei Zhang; Minh Vu Chuong Nguyen; Bernard Lardy; Algirdas J Jesaitis; Alexei Grichine; Francis Rousset; Monique Talbot; Marie-Hélène Paclet; Guanxiang Qian; Françoise Morel
Journal:  Biochimie       Date:  2010-11-12       Impact factor: 4.079

3.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.

Authors:  Takashi Sato; Xiaochuan Yang; Steven Knapper; Paul White; B Douglas Smith; Steven Galkin; Donald Small; Alan Burnett; Mark Levis
Journal:  Blood       Date:  2011-01-24       Impact factor: 22.113

5.  NADPH oxidase activation in pancreatic cancer cells is mediated through Akt-dependent up-regulation of p22phox.

Authors:  Mouad Edderkaoui; Claudia Nitsche; Ling Zheng; Stephen J Pandol; Ilya Gukovsky; Anna S Gukovskaya
Journal:  J Biol Chem       Date:  2010-11-30       Impact factor: 5.157

Review 6.  Role of FLT3 in leukemia.

Authors:  D Gary Gilliland; James D Griffin
Journal:  Curr Opin Hematol       Date:  2002-07       Impact factor: 3.284

7.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.

Authors:  F Hayakawa; M Towatari; H Kiyoi; M Tanimoto; T Kitamura; H Saito; T Naoe
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

Review 8.  Repair of oxidative DNA damage: mechanisms and functions.

Authors:  A L Lu; X Li; Y Gu; P M Wright; D Y Chang
Journal:  Cell Biochem Biophys       Date:  2001       Impact factor: 2.194

9.  Subcellular localization of Nox4 and regulation in diabetes.

Authors:  Karen Block; Yves Gorin; Hanna E Abboud
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

Review 10.  Multiple mutations and cancer.

Authors:  Lawrence A Loeb; Keith R Loeb; Jon P Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

View more
  34 in total

Review 1.  Therapeutic potential of NADPH oxidase 1/4 inhibitors.

Authors:  G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood
Journal:  Br J Pharmacol       Date:  2016-07-14       Impact factor: 8.739

Review 2.  Obesity and cancer: A mechanistic overview of metabolic changes in obesity that impact genetic instability.

Authors:  Pallavi Kompella; Karen M Vasquez
Journal:  Mol Carcinog       Date:  2019-06-05       Impact factor: 4.784

Review 3.  Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Authors:  Melanie T Rebechi; Keith W Pratz
Journal:  Leuk Lymphoma       Date:  2017-02-06

4.  Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia.

Authors:  Daniela Di Marcantonio; Esteban Martinez; Simone Sidoli; Jessica Vadaketh; Margaret Nieborowska-Skorska; Anushk Gupta; Jake M Meadows; Francesca Ferraro; Elena Masselli; Grant A Challen; Michael D Milsom; Claudia Scholl; Stefan Fröhling; Siddharth Balachandran; Tomasz Skorski; Benjamin A Garcia; Prisco Mirandola; Giuliana Gobbi; Ramiro Garzon; Marco Vitale; Stephen M Sykes
Journal:  Clin Cancer Res       Date:  2017-11-10       Impact factor: 12.531

Review 5.  Hematopoietic Stem Cells: Normal Versus Malignant.

Authors:  Dustin Carroll; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2017-12-20       Impact factor: 8.401

Review 6.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

7.  MnTE-2-PyP modulates thiol oxidation in a hydrogen peroxide-mediated manner in a human prostate cancer cell.

Authors:  Qiang Tong; Yuxiang Zhu; Joseph W Galaske; Elizabeth A Kosmacek; Arpita Chatterjee; Bryan C Dickinson; Rebecca E Oberley-Deegan
Journal:  Free Radic Biol Med       Date:  2016-09-24       Impact factor: 7.376

8.  Reactive Oxygen Species Drive Proliferation in Acute Myeloid Leukemia via the Glycolytic Regulator PFKFB3.

Authors:  Andrew J Robinson; Goitseone L Hopkins; Namrata Rastogi; Marie Hodges; Michelle Doyle; Sara Davies; Paul S Hole; Nader Omidvar; Richard L Darley; Alex Tonks
Journal:  Cancer Res       Date:  2019-12-20       Impact factor: 12.701

Review 9.  Carcinogenesis and Reactive Oxygen Species Signaling: Interaction of the NADPH Oxidase NOX1-5 and Superoxide Dismutase 1-3 Signal Transduction Pathways.

Authors:  Alessia Parascandolo; Mikko O Laukkanen
Journal:  Antioxid Redox Signal       Date:  2018-11-22       Impact factor: 8.401

10.  Genetic deletion of Nox4 enhances cancerogen-induced formation of solid tumors.

Authors:  Valeska Helfinger; Florian Freiherr von Gall; Nina Henke; Michael M Kunze; Tobias Schmid; Flavia Rezende; Juliana Heidler; Ilka Wittig; Heinfried H Radeke; Viola Marschall; Karen Anderson; Ajay M Shah; Simone Fulda; Bernhard Brüne; Ralf P Brandes; Katrin Schröder
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.